Search Results | MSF Science Portal

Journal Article

|

Research

Huerga H, Gouillou M, Ohler L, Taremwa IM, Akinyi M, et al.

2025-04-23 • PLOS Global Public Health

People living with HIV (PLHIV) have an increased risk of tuberculosis (TB) and severe COVID-19. TB and COVI...

Journal Article

|

Research

Ardizzoni E, Mulders W, De Diego Fuertes M, Hayrapetyan A, Mirzoyan A, et al.

2025-04-09 • Antimicrobial Agents and Chemotherapy

Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenia...

Journal Article

|

Research

Khan U, Rich M, Franke M, Lachenal N, Ahmed S, et al.

2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Conference Material

|

Abstract

Bastard M

2024-05-23 • Epicentre Scientific Day 2024

BACKGROUND
Children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are under diagnosed and under treated. Few reports exist on the treatme...

Journal Article

|

Research

Kho S, Seung KJ, Huerga H, Bastard M, Khan PY, et al.

2024-05-09 • Nature Communications

Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT032592...

Journal Article

|

Research

Coulborn RM, Bastard M, Peyraud N, Gignoux EM, Luquero FJ, et al.

2024-02-01 • Lancet Infectious Diseases

BACKGROUND
The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease outbreaks. This retrospective cohort study aimed to assess the protective effect of ...

Journal Article

|

Research

Sauer SM, Mitnick CD, Khan UT, Hewison CCH, Bastard M, et al.

2024-01-25 • Clinical Infectious Diseases

BACKGROUND
Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). Howev...

Journal Article

|

Research

Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD, et al.

2024-01-20 • medRxiv

RATIONALE

Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resis...

Journal Article

|

Research

Klein A, Bastard M, Hemat H, Singh SN, Muniz B, et al.

2023-08-24 • PLOS Global Public Health

Though many studies on COVID have been published to date, data on COVID-19 epidemiology, symptoms, risk factors and severity in low- and middle-income countries (LMICS), such as Afghanis...

Journal Article

|

Research

Trevisi L, Hernán MA, Mitnick CD, Khan UT, Seung KJ, et al.

2023-06-01 • American Journal of Respiratory and Critical Care Medicine

RATIONALE
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...

Journal Article

|

Research

Rich ML, Khan UT, Zeng C, LaHood AN, Franke MF, et al.

2023-06-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.

OB...

Journal Article

|

Research

Broger T, Koeppel L, Huerga H, Miller P, Gupta-Wright A, et al.

2023-06-01 • Lancet Global Health

BACKGROUND
Sputum is the most widely used sample to diagnose active tuberculosis, but many people living with HIV are unable to produce sputum. Urine, in contrast, is readily availab...

Journal Article

|

Research

Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M, et al.

2023-04-28 • PLOS Global Public Health

Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb tr...

Journal Article

|

Pre-Print

Klein A, Bastard M, Hemat H, Singh SN, Muniz B, et al.

2023-02-16 • medRxiv

BACKGROUND
Though many studies on COVID have been published to date, data on COVID-19 epidemiology, symptoms, risk factors and severity in low- and middle-income countries (LMICS), s...

Journal Article

|

Research

Grout L, Katuala Givo Y, Newport T, Mahamat TA, Gitahi P, et al.

2023-02-06 • Malaria Journal

BACKGROUND
Angumu health zone in Ituri, Democratic Republic of Congo, is a highly malaria-endemic area with an overburdened health system and hosting internally displaced persons (ID...

Journal Article

|

Research

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY, et al.

2023-01-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...

Journal Article

|

Research

Huerga H, Bastard M, Lubega AV, Akinyi M, Antabak NT, et al.

2023-01-01 • Lancet Global Health

BACKGROUND
Development of rapid biomarker-based tests that can diagnose tuberculosis using non-sputum samples is a priority for tuberculosis control. We aimed to compare the diagnost...

Journal Article

|

Research

Rodriguez CA, Lodi S, Horsburgh CR, Bastard M, Hewison C, et al.

2022-11-10 • PLOS One

BACKGROUND

Journal Article

|

Research

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N, et al.

2022-10-15 • Clinical Infectious Diseases

BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...

Journal Article

|

Research

Hewison CCH, Khan UT, Bastard M, Lachenal N, Coutisson S, et al.

2022-09-15 • Clinical Infectious Diseases

RATIONALE
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.

OBJECTIVES
Evaluate safety of longer MDR/RR-TB...

Science Portal

COVID-19, tuberculosis, and HIV triad: a prospective observational study in ambulatory patients in Kenya, Uganda, and South Africa

Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Treatment of children and adolescents with MDR/RR-TB regimens containing bédaquiline and delamanid: results from the endTB observational study

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis

Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo

Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up

Effectiveness of a bedaquiline, linezolid, clofazimine “core” for multidrug-resistant tuberculosis

Factors associated with adverse outcomes among patients hospitalized at a COVID-19 treatment center in Herat, Afghanistan

Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective

Factors associated with adverse outcomes among patients hospitalized at a COVID-19 treatment center run by Médecins sans Frontières in Herat, Afghanistan

Effect of large-scale mass drug administration for malaria on mortality and morbidity in Angumu health zone, Ituri, Democratic Republic of Congo

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study

Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion

BACKGROUND

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort